Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 8/20 | 0.58 |
| ▸ | CCR2 | P41597 | 1/20 | 0.43 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.42 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | CECR2 | Q9BXF3 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | FYN | P06241 | 1/20 | 0.40 |
| ▸ | ERN1 | O75460 | 1/20 | 0.39 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22021593 | 0.85 | ACLY (0.58) | ACLYCECR2FYNERN1 | |
| SCHEMBL22004311 | 0.82 | ACLY (0.55) | ACLYFYNERN1 | |
| SCHEMBL8648612 | 0.77 | GRIK1 (0.65) | ACLYCCR2GRIK1GRIK2TDP1 | |
| SCHEMBL22003789 | 0.76 | ACLY (0.51) | ACLYCCR2TDP1 | |
| SCHEMBL22004217 | 0.74 | ACLY (1.00) | ACLY | |
| SCHEMBL18470548 | 0.73 | GRIK1 (0.49) | ACLYGRIK1GRIK2TDP1MAPT | |
| SCHEMBL12472078 | 0.73 | ERN1 (0.56) | MAPTERN1 | |
| SCHEMBL17199126 | 0.72 | GRIK1 (0.48) | GRIK1GRIK2TDP1MAPT | |
| SCHEMBL22004304 | 0.71 | ACLY (0.63) | ACLYCCR2 | |
| SCHEMBL22004299 | 0.71 | ACLY (0.59) | ACLY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200157076-A1 | ACLY INHIBITORS AND USES THEREOF | NIMBUS DISCOVERY, INC. | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200157076-A1 | ACLY INHIBITORS AND USES THEREOF | ACLY, ATP5ME, ATP5MG | ACLY 1/4885CCR2 4510/4885GRIK1 1471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.